Molecular Templates — Cowen Presentation (March 2022)
21 slides from Molecular Templates's conference presentation, Mar 8, 2022
Slide 1: Molecular Templates: Next Generation Immunotoxins
Molecular templates Next generation immunotoxins Cowen Presentation Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the de
Slide 3: Developing Novel Oncology Therapies with Differentiated Technology Platform
Developing Novel Oncology Therapies with Differentiated Technology Platform Unique MOA and I/O approach Unique biological MOA of: (i) forced cellular internalization once bound to target and (ii) potent direct cell kill via enzymatic ribosome destruction Delivery of viral antigens to redirect reside
Slide 4: The Engineered Toxin Body (ETB) Platform: Targeted Biologics with Novel MOAs
The Engineered Toxin Body (ETB) Platform: Targeted Biologics with Novel MOAs Catalytical active A-subunit (SLT-A) Binds CD77 (non-internalizing GSL) and mediates its own internalization A-subunit mediates translocation to cytosol and enzymatically destroys ribosome CD77 binding B-subunit ETBs Retain
Slide 5: I/O Approach: MT-6402 Direct PD-L1 Targeted Cell-Kill and Antigen Seeding
I/o approach: MT-6402 direct PD-L1 Targeted cell-kill and antigen seeding
Slide 6: Immune Phenotype May Determine Sensitivity to PD-L1 Checkpoint Therapies
Immune phenotype may determine sensitivity to PD-L1 checkpoint therapies Myeloid derived suppressive cells (MDSCs) express PD-L1 and promote an immunosuppressive tumor microenvironment Frequency of peripheral PD-L1+ monocytes predicts responses to CTLA-4 and PD-1 inhibitors High frequency of periphe
Slide 7: MT-6402: Dual MOA Targeting PD-L1
MT-6402: Dual MOA targeting PD-L1 Destroys PD-L1 Expressing Cells – MOA1 Potent direct cell-kill (pM) against PD-L1+ tumor cells Potent direct cell-kill (pM) against PD-L1+ immune cells to activate the immune system Antigen Seeding Technology (AST) – MOA2 Delivers pp65 CMV antigen for cell surface e
Slide 8: MT-6402 Ongoing Phase 1: Unique PD Effects With Signs of Clinical Benefit
MT-6402 Ongoing Phase 1: Unique PD Effects With Signs of Clinical Benefit No DLTs observed in 16 mcg/kg cohort; dose escalation on-going at 24 mcg/kg No safety concerns noted to date NSCLC pt with non-measurable bone disease saw resolution of 3 out of 4 lesions and reduction in uptake with remaining
Slide 9: MT-6402: Early Signals of Antigen Seeding MOA in Phase 1
MT-6402: Early Signals of Antigen Seeding MOA in Phase 1 Subject 001 – HLA-A2 CMV+ patient (i.e., antigen-seeing eligible patient) NSCLC chemotherapy-ineligible patient whose disease had progressed following treatment with a combination of checkpoint inhibitors (ipilimumab and nivolumab); patient ha
Slide 10: Anti-CTLA-4 ETB: Differentiated I/O Approach Targeting CTLA-4
Anti-CTLA-4 ETB Differentiated I/o approach targeting ctla-4
Slide 11: CTLA-4 Targeting ETB IND Filing Expected in 2H22
CTLA-4 targeting ETB IND filing expected in 2H22 Tregs in the TME express high levels of CTL-4 and can drive immunosuppressive tumor microenvironment CTLA-4 targeting ETB has a potent mechanism of CTLA-4 targeted cell-kill that may not be subject to immunosuppression ETB approach is designed to avoi
Slide 12: MT-5111 Anti-HER2 ETB
W\/xtem MOLECULAR TEMPLATES MT-5111 ANTI-HER2 ETB
Slide 13: HER2 Remains a Key Target for Breast Cancer
HER2 Remains a Key Target for Breast Cancer Recent advances confirm responsiveness of breast cancer to new MOAs targeting HER2 Despite high response rates and longer durations of response, recent ADCs are not cures and unmet need for metastatic patients will remain Demand for new mechanisms of actio
Slide 14: MT-5111: Anti-HER2 ETB with Differentiated Binding and MOA Profile
MT-5111: Anti-HER2 ETB with Differentiated Binding and MOA profile Binds HER2 at a distinct epitope from trastuzumab and pertuzumab De-immunized Shiga-Like Toxin (SLT-A) Payload Reduced TLR4 interaction to minimize innate triggering (CLS) Potent direct cell kill (pM) against HER2 expressing cancer c
Slide 15: MT-5111: Dose Levels at 10 mcg/kg or Higher Likely Needed for Activity
MT-5111: Dose Levels at 10 mcg/kg or Higher Likely Needed for Activity 27 patients dosed with no DLTs or CLS observed to date - dose escalation continues Dose level at 13 mcg/kg and breast cancer dose expansion cohort (10 mcg/kg) currently enrolling with >20 sites open MT-5111 Cmax (ng/mL) at 10 mcg
Slide 16: MT-0169 Anti-CD38 ETB
WYXtem MOLECULAR TEMPLATES MT-0169 ANTI-CD38 ETB ip
Slide 17: CD38 Remains a Key Target in Myeloma with Limited Available Modalities
CD38 Remains a Key Target in Myeloma with Limited Available Modalities Mabs are currently the only validated modality targeting CD38 Lack of CD38 internalization prohibits ADC development and promiscuity of target may deter CAR-T and bispecifics BCMA for myeloma has been more tenable target for mult
Slide 18: MT-0169: New Modality Targeting CD38
MT-0169: New Modality Targeting CD38 Binds CD38 with high specificity and potency retained even in presence of daratumumab (overlapping epitope) De-immunized Shiga-Like Toxin (SLT-A) Payload Reduced TLR4 interaction to minimize innate triggering (CLS) Potent direct cell kill against CD38 expressing
Slide 19: MT-0169: PD Activity Observed in Phase 1 and Safety Signals
MT-0169: PD Activity Observed in Phase 1 and Safety Signals Five pts treated to date with two pts with cardiac AEs that meet criteria for DLT Evaluation of both AEs triggered by asymptomatic elevations in high-sensitivity troponin The first DLT was an asymptomatic, rapidly reversible episode of myoc
Slide 20: Corporate Summary
Corporate Summary Clinical data milestones expected across three ETB programs in 2022 MT-6402 demonstrating early signs of clinical benefit and pharmacodynamic activity MT-5111 drug exposure levels now in therapeutic range MT-0169 shows potent pharmacodynamic activity; moving forward with dose reduc
Slide 21: Advancing Wholly Owned Clinical Pipeline with Novel MOAs
Advancing Wholly Owned Clinical Pipeline with Novel MOAs ETB Program Target MOA Indication MT-6402 PD-L1 Direct cell kill Antigen Seeding (CMV antigen) Solid Tumors MT-5111 HER2 Direct cell-kill Breast Cancer MT-0169 CD38 Direct cell-kill Multiple Myeloma ETB Candidate CTLA-4 Direct cell-kill Solid
Molecular Templates — Cowen Presentation (March 2022) on 6ix